Congenital Bile Acid Synthesis Defect Type 1: A Patient Guide
At a Glance
CBAS1 (HSD3B7 deficiency) causes bile buildup, jaundice, and poor growth because the liver cannot make the bile acids needed for digestion. Early cholic acid replacement can improve nutrient absorption and liver health, while advanced scarring may require transplant evaluation.
Congenital Bile Acid Synthesis Defect Type 1 (CBAS1), also known as HSD3B7 deficiency, is an extremely rare genetic condition that changes how the liver processes the building blocks of digestion. In a healthy body, the liver creates primary bile acids, which act like biological detergents to help emulsify and absorb fats and fat-soluble vitamins, while also flushing out waste. In children with CBAS1, a missing enzyme (the HSD3B7 protein) creates a metabolic roadblock, preventing the liver from completing this vital process [1]. This leads to a dual challenge: the body cannot absorb essential fats and vitamins, and the liver struggles as abnormal, alternative bile acids are produced and accumulate [2].
Infants with this condition typically show signs of cholestasis (a backup of bile), which often appears as persistent yellowing of the skin and eyes (jaundice) [3]. Over time, parents may also notice that their child is struggling to gain weight or grow at a normal rate [4]. Identifying this condition can be tricky because it often lacks the high markers of liver stress (such as a high GGT level) that doctors expect to see in other neonatal liver diseases [5]. Finding this unique “laboratory fingerprint” of low or normal GGT alongside low or normal serum bile acids is a critical clue [2].
The most vital thing for a family to know is that CBAS1 has a specific, targeted treatment. By using primary bile acid replacement therapy (such as cholic acid), doctors provide the body with the exact acids it is unable to make on its own [6]. This treatment helps satisfy the body’s need for nutrients while signaling the liver to stop producing the abnormal acids [7].
Many children respond very well to early treatment, with stabilized liver health and improved development. However, outcome depends heavily on the age at treatment, any existing liver scarring (fibrosis or cirrhosis), and adherence to the regimen; some children with advanced disease may still require liver transplant evaluation [8][9].
What You Need to Do Now
- Confirm Your Team: Ensure your child is being evaluated by a pediatric hepatologist and a biochemical geneticist.
- Understand Instructions: Obtain exact administration guidelines for bile acid therapy (Cholbam) and prescribed vitamin supplements. Do not alter doses independently.
- Emergency Plan: Know the after-hours contact number for your specialist team and learn the red-flag symptoms for bleeding and infant distress.
- Prepare Records: Gather your child’s complete lab history, urine mass spectrometry results, and genetic reports for your specialist visits.
In this guide
6 chapters
Understanding CBAS1: A Guide for Parents and Guardians
Learn what CBAS1 (HSD3B7 deficiency) means for your child, including liver effects, bile acid treatment, vitamin absorption, inheritance, and family planning.
Recognizing Symptoms and Emergency Red Flags
Learn CBAS1 (HSD3B7 deficiency) symptoms in children, including jaundice, vitamin K bleeding risk, and when to call the specialist or seek emergency care.
The Diagnostic Path: Testing and Look-Alikes
Learn how CBAS1 is diagnosed using GGT, serum bile acids, urine mass spectrometry, HSD3B7 genetic testing, and evaluation for biliary atresia in infants.
Standard of Care: Bile Acid Replacement Therapy
Learn about congenital bile acid synthesis defect type 1 treatment, including cholic acid dosing, vitamin support, liver tests, side effects, and monitoring.
Building Your Child's Care Team and Preparing for Visits
Learn how to build a care team for CBAS1 (HSD3B7 deficiency), prepare records for specialist visits, and create an emergency medication plan for your child.
Looking Ahead: Long-Term Monitoring and Health
Learn how CBAS1 long-term monitoring protects your child's liver through bile acid profiles, blood tests, vitamins, growth, bone, and kidney checks over time.
Common questions in this guide
What is congenital bile acid synthesis defect type 1 (CBAS1)?
What signs might suggest CBAS1 in a baby?
How do doctors look for CBAS1?
What treatment is used for HSD3B7 deficiency?
Can early treatment improve a child's outlook with CBAS1?
Which specialists should care for a child with CBAS1?
Get notified when new evidence is published on Congenital bile acid synthesis defect type 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
Substrate specificity and kinetic mechanism of 3β-hydroxy-Δ5-C27-steroid oxidoreductase.
Gardner SM, Vogt A, Penning TM, Marmorstein R
The Journal of biological chemistry 2024; (300(12)):107945 doi:10.1016/j.jbc.2024.107945.
PMID: 39505210 - 2
[Infant with 3β-hydroxy-Δ(5)-C27 steroid dehydrogenase deficiency: report of two cases and literatures review].
Li X, Huang Z, Wang H
Zhonghua er ke za zhi = Chinese journal of pediatrics 2015; (53(5)):360-5.
PMID: 26080666 - 3
Bile Acid Synthesis Disorder Masquerading as Intractable Vitamin D-Deficiency Rickets.
Ahmad O, Nogueira J, Heubi JE, et al.
Journal of the Endocrine Society 2019; (3(2)):397-402 doi:10.1210/js.2018-00314.
PMID: 30746501 - 4
Open-label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis.
Heubi JE, Setchell KDR
Journal of pediatric gastroenterology and nutrition 2020; (70(4)):423-429 doi:10.1097/MPG.0000000000002618.
PMID: 31899729 - 5
Inborn errors of bile acid metabolism in Japan.
Mizuochi T, Takei H, Nittono H, Kimura A
Pediatrics international : official journal of the Japan Pediatric Society 2023; (65(1)):e15490 doi:10.1111/ped.15490.
PMID: 36704863 - 6
Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood.
Gonzales E, Matarazzo L, Franchi-Abella S, et al.
Orphanet journal of rare diseases 2018; (13(1)):190 doi:10.1186/s13023-018-0920-5.
PMID: 30373615 - 7
Tandem mass spectrometric determination of atypical 3β-hydroxy-Δ5-bile acids in patients with 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency: application to diagnosis and monitoring of bile acid therapeutic response.
Zhang W, Jha P, Wolfe B, et al.
Clinical chemistry 2015; (61(7)):955-63 doi:10.1373/clinchem.2015.238238.
PMID: 25931455 - 8
Atypical clinical presentation and successful treatment with oral cholic acid of a child with defective bile acid synthesis due to a novel mutation in the HSD3B7 gene.
Bossi G, Giordano G, Rispoli GA, et al.
Pediatric reports 2017; (9(3)):7266 doi:10.4081/pr.2017.7266.
PMID: 29081931 - 9
Genetic spectrum and clinical characteristics of 3β-hydroxy-Δ5-C27-steroid oxidoreductase (HSD3B7) deficiency in China.
Zhao J, Setchell KDR, Gong Y, et al.
Orphanet journal of rare diseases 2021; (16(1)):417 doi:10.1186/s13023-021-02041-7.
PMID: 34627351
This page is for informational purposes only and does not constitute medical advice. Your child's pediatric hepatologist and biochemical geneticist should interpret test results and guide treatment.